Oz Biomedical and Wollerau Capital Partners Limited, together for the global distribution of the Gmate® COVID-19
PRESS RELEASE OZ BIOMEDICAL
Oz Biomedical, which has always been involved in the marketing of ecological and avant-garde machinery aimed at preserving nature and protecting man, entered into a strategic agreement on 21/05/2020 with Wollerau Capital Partners Limited for the global distribution of the product: Gmate® COVID-19.
“Wollerau Capital Partners” is a large holding company present in almost all world territories that collaborates with important world groups and distributes medical devices through its subsidiary, the British company Wollerau Pharma.
To date, the Gmate Reader® is the most efficient and technologically advanced product on the market. Already authorized and certified at European and Asian level, in a few weeks it will be approved by the American FDA for its rapid diffusion.